Cumulative incidence of all-cause mortality rate in Chagas and non-Chagas patients.

<p>Cumulative incidence of all-cause mortality rate in Chagas and non-Chagas patients.</p

Cox proportional hazard analysis of risk factors at baseline for sudden death mortality.

<p>Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CrCl, creatinine clearance; EC, emergency care; Hosp, hospitalization; NYHA, New York Heart Association functional class; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; NA: not applicable; NS: not significant;</p>a<p>NYHA class III/VI vs NYHA class I/II;</p>b<p>Chagas vs non Chagas;</p>c<p>beta-blocker vs no beta-blocker;</p>d<p>ACEI/ARB vs no ACEI/ARB;</p>e<p>spironolactone vs no spironolactone;</p>f<p>amiodarone vs no amiodarone;</p>g<p>disease management program vs control;</p>h<p>Model 1 not incorporated NYHA functional class and Model 2 included NYHA functional class (information available in 296 patients).</p

Cumulative incidence of sudden death mortality rate in Chagas and non-Chagas patients.

<p>Cumulative incidence of sudden death mortality rate in Chagas and non-Chagas patients.</p

Follow-up comparisons between groups.

<p>Abbreviations: IQR, interquartile range.</p

Characteristics of the study population.

<p>Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CrCl, creatinine clearance; NYHA, New York Heart Association functional class; IQR, interquartile range; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter.</p>*<p>Information available in 296 patients.</p

Cox proportional hazard analysis of risk factors at baseline for heart failure mortality.

<p>Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CrCl, creatinine clearance; EC, emergency care; Hosp, hospitalization; NYHA, New York Heart Association functional class; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; NA: not applicable; NS: not significant;</p>a<p>NYHA class III/VI vs NYHA class I/II;</p>b<p>Chagas vs non Chagas;</p>c<p>beta-blocker vs no beta-blocker;</p>d<p>ACEI/ARB vs no ACEI/ARB;</p>e<p>spironolactone vs no spironolactone;</p>f<p>amiodarone vs no amiodarone;</p>g<p>disease management program vs control;</p>h<p>Model 1 not incorporated NYHA functional class and Model 2 included NYHA functional class (information available in 296 patients).</p

Cumulative incidence of heart failure mortality rate in Chagas and non-Chagas patients.

<p>Cumulative incidence of heart failure mortality rate in Chagas and non-Chagas patients.</p

Flow diagram of the REMADHE trial.

<p>Flow diagram of the REMADHE trial.</p